Search for "urea" in Full Text gives 225 result(s) in Beilstein Journal of Organic Chemistry. Showing first 200.
Beilstein J. Org. Chem. 2014, 10, 774–783, doi:10.3762/bjoc.10.73
Graphical Abstract
Scheme 1: (a) Staudinger reaction (b) Staudinger ligation, (c) the cyclodextrin structure with glucopyranose ...
Scheme 2: (a) i) HCl, NaNO2/H2O, then KI/H2O, 58%, ii) Ph2PH, Pd(OAc)2, Et3N, MeOH, 48%; (b) i) CH3COOH, H2SO4...
Scheme 3: Staudinger ligation reactions: (a) Preparation of 4 from mono[6-(3-azidopropylamino)-6-deoxy]-β-CD ...
Figure 1: 1H NMR chemical shift change (Δδ) of CD cavity Η3 signal of compounds titrated with 1-adamantylamin...
Figure 2: The most stable conformations of 4 at the PM3(COSMO) level of theory: (a) open, (b) vicinal, and (c...
Figure 3: Typical conformations of 6: (a) open conformation, (b) vicinal, (c) inclusion/vicinal and (d) doubl...
Beilstein J. Org. Chem. 2014, 10, 544–598, doi:10.3762/bjoc.10.50
Graphical Abstract
Scheme 1: The proposed mechanism of the Passerini reaction.
Scheme 2: The PADAM-strategy to α-hydroxy-β-amino amide derivatives 7. An additional oxidation provides α-ket...
Scheme 3: The general accepted Ugi-mechanism.
Scheme 4: Three commonly applied Ugi/cyclization approaches. a) UDC-process, b) UAC-sequence, c) UDAC-combina...
Scheme 5: Ugi reaction that involves the condensation of Armstrong’s convertible isocyanide.
Scheme 6: Mechanism of the U-4C-3CR towards bicyclic β-lactams.
Scheme 7: The Ugi 4C-3CR towards oxabicyclo β-lactams.
Scheme 8: Ugi MCR between an enantiopure monoterpene based β-amino acid, aldehyde and isocyanide resulting in...
Scheme 9: General MCR for β-lactams in water.
Scheme 10: a) Ugi reaction for β-lactam-linked peptidomimetics. b) Varying the β-amino acid resulted in β-lact...
Scheme 11: Ugi-4CR followed by a Pd-catalyzed Sn2 cyclization.
Scheme 12: Ugi-3CR of dipeptide mimics from 2-substituted pyrrolines.
Scheme 13: Joullié–Ugi reaction towards 2,5-disubstituted pyrrolidines.
Scheme 14: Further elaboration of the Ugi-scaffold towards bicyclic systems.
Scheme 15: Dihydroxyproline derivatives from an Ugi reaction.
Scheme 16: Diastereoselective Ugi reaction described by Banfi and co-workers.
Scheme 17: Similar Ugi reaction as in Scheme 16 but with different acids and two chiral isocyanides.
Scheme 18: Highly diastereoselective synthesis of pyrrolidine-dipeptoids via a MAO-N/MCR-procedure.
Scheme 19: MAO-N/MCR-approach towards the hepatitis C drug telaprevir.
Scheme 20: Enantioselective MAO-U-3CR procedure starting from chiral pyrroline 64.
Scheme 21: Synthesis of γ-lactams via an UDC-sequence.
Scheme 22: Utilizing bifunctional groups to provide bicyclic γ-lactam-ketopiperazines.
Scheme 23: The Ugi reaction provided both γ- as δ-lactams depending on which inputs were used.
Scheme 24: The sequential Ugi/RCM with olefinic substrates provided bicyclic lactams.
Scheme 25: a) The structural and dipole similarities of the triazole unit with the amide bond. b) The copper-c...
Scheme 26: The Ugi/Click sequence provided triazole based peptidomimetics.
Scheme 27: The Ugi/Click reaction as described by Nanajdenko.
Scheme 28: The Ugi/Click-approach by Pramitha and Bahulayan.
Scheme 29: The Ugi/Click-combination by Niu et al.
Scheme 30: Triazole linked peptidomimetics obtained from two separate MCRs and a sequential Click reaction.
Scheme 31: Copper-free synthesis of triazoles via two MCRs in one-pot.
Scheme 32: The sequential Ugi/Paal–Knorr reaction to afford pyrazoles.
Scheme 33: An intramolecular Paal–Knorr condensation provided under basic conditions pyrazolones.
Scheme 34: Similar cyclization performed under acidic conditions provided pyrazolones without the trifluoroace...
Scheme 35: The Ugi-4CR towards 2,4-disubstituted thiazoles.
Scheme 36: Solid phase approach towards thiazoles.
Scheme 37: Reaction mechanism of formation of thiazole peptidomimetics containing an additional β-lactam moiet...
Scheme 38: The synthesis of the trisubstituted thiazoles could be either performed via an Ugi reaction with pr...
Scheme 39: Performing the Ugi reaction with DMB-protected isocyanide gave access to either oxazoles or thiazol...
Scheme 40: Ugi/cyclization-approach towards 2,5-disubstituted thiazoles. The Ugi reaction was performed with d...
Scheme 41: Further derivatization of the thiazole scaffold.
Scheme 42: Three-step procedure towards the natural product bacillamide C.
Scheme 43: Ugi-4CR to oxazoles reported by Zhu and co-workers.
Scheme 44: Ugi-based synthesis of oxazole-containing peptidomimetics.
Scheme 45: TMNS3 based Ugi reaction for peptidomimics containing a tetrazole.
Scheme 46: Catalytic cycle of the enantioselective Passerini reaction towards tetrazole-based peptidomimetics.
Scheme 47: Tetrazole-based peptidomimetics via an Ugi reaction and a subsequent sigmatropic rearrangement.
Scheme 48: Resin-bound Ugi-approach towards tetrazole-based peptidomimetics.
Scheme 49: Ugi/cyclization approach towards γ/δ/ε-lactam tetrazoles.
Scheme 50: Ugi-3CR to pipecolic acid-based peptidomimetics.
Scheme 51: Staudinger–Aza-Wittig/Ugi-approach towards pipecolic acid peptidomimetics.
Figure 1: The three structural isomers of diketopiperazines. The 2,5-DKP isomer is most common.
Scheme 52: UDC-approach to obtain 2,5-DKPs, either using Armstrong’s isocyanide or via ethylglyoxalate.
Scheme 53: a) Ugi reaction in water gave either 2,5-DKP structures or spiro compounds. b) The Ugi reaction in ...
Scheme 54: Solid-phase approach towards diketopiperazines.
Scheme 55: UDAC-approach towards DKPs.
Scheme 56: The intermediate amide is activated as leaving group by acid and microwave assisted organic synthes...
Scheme 57: UDC-procedure towards active oxytocin inhibitors.
Scheme 58: An improved stereoselective MCR-approach towards the oxytocin inhibitor.
Scheme 59: The less common Ugi reaction towards DKPs, involving a Sn2-substitution.
Figure 2: Spatial similarities between a natural β-turn conformation and a DKP based β-turn mimetic [158].
Scheme 60: Ugi-based syntheses of bicyclic DKPs. The amine component is derived from a coupling between (R)-N-...
Scheme 61: Ugi-based synthesis of β-turn and γ-turn mimetics.
Figure 3: Isocyanide substituted 3,4-dihydropyridin-2-ones, dihydropyridines and the Freidinger lactams. Bio-...
Scheme 62: The mechanism of the 4-CR towards 3,4-dihydropyridine-2-ones 212.
Scheme 63: a) Multiple MCR-approach to provide DHP-peptidomimetic in two-steps. b) A one-pot 6-CR providing th...
Scheme 64: The MCR–alkylation–MCR procedure to obtain either tetrapeptoids or depsipeptides.
Scheme 65: U-3CR/cyclization employing semicarbazone as imine component gave triazine based peptidomimetics.
Scheme 66: 4CR towards triazinane-diones.
Scheme 67: The MCR–alkylation–IMCR-sequence described by our group towards triazinane dione-based peptidomimet...
Scheme 68: Ugi-4CR approaches followed by a cyclization to thiomorpholin-ones (a) and pyrrolidines (b).
Scheme 69: UDC-approach for benzodiazepinones.
Scheme 70: Ugi/Mitsunobu sequence to BDPs.
Scheme 71: A UDAC-approach to BDPs with convertible isocyanides. The corresponding amide is cleaved by microwa...
Scheme 72: microwave assisted post condensation Ugi reaction.
Scheme 73: Benzodiazepinones synthesized via the post-condensation Ugi/ Staudinger–Aza-Wittig cyclization.
Scheme 74: Two Ugi/cyclization approaches utilizing chiral carboxylic acids. Reaction (a) provided the product...
Scheme 75: The mechanism of the Gewald-3CR includes three base-catalysed steps involving first a Knoevnagel–Co...
Scheme 76: Two structural 1,4-thienodiazepine-2,5-dione isomers by U-4CR/cyclization.
Scheme 77: Tetrazole-based diazepinones by UDC-procedure.
Scheme 78: Tetrazole-based BDPs via a sequential Ugi/hydrolysis/coupling.
Scheme 79: MCR synthesis of three different tricyclic BPDs.
Scheme 80: Two similar approaches both involving an Ugi reaction and a Mitsunobu cyclization.
Scheme 81: Mitsunobu–Ugi-approach towards dihydro-1,4-benzoxazepines.
Scheme 82: Ugi reaction towards hetero-aryl fused 5-oxo-1,4-oxazepines.
Scheme 83: a) Ugi/RCM-approach towards nine-membered peptidomimetics b) Sequential peptide-coupling, deprotect...
Scheme 84: Ugi-based synthesis towards cyclic RGD-pentapeptides.
Scheme 85: Ugi/MCR-approach towards 12–15 membered macrocycles.
Scheme 86: Stereoselective Ugi/RCM approach towards 16-membered macrocycles.
Scheme 87: Passerini/RCM-sequence to 22-membered macrocycles.
Scheme 88: UDAC-approach towards 12–18-membered depsipeptides.
Figure 4: Enopeptin A with its more active derivative ADEP-4.
Scheme 89: a) The Joullié–Ugi-approach towards ADEP-4 derivatives b) Ugi-approach for the α,α-dimethylated der...
Scheme 90: Ugi–Click-strategy for 15-membered macrocyclic glyco-peptidomimetics.
Scheme 91: Ugi/Click combinations provided macrocycles containing both a triazole and an oxazole moiety.
Scheme 92: a) A solution-phase procedure towards macrocycles. b) Alternative solid-phase synthesis as was repo...
Scheme 93: Ugi/cyclization towards cyclophane based macrocycles.
Scheme 94: PADAM-strategy towards eurystatin A.
Scheme 95: PADAM-approach for cyclotheanamide.
Scheme 96: A triple MCR-approach affording RGD-pentapeptoids.
Scheme 97: Ugi-MiBs-approach towards peptoid macrocycles.
Scheme 98: Passerini-based MiB approaches towards macrocycles 345 and 346.
Scheme 99: Macrocyclic peptide formation by the use of amphoteric aziridine-based aldehydes.
Beilstein J. Org. Chem. 2014, 10, 481–513, doi:10.3762/bjoc.10.46
Graphical Abstract
Scheme 1: General reaction mechanism for Ag(I)-catalyzed A3-coupling reactions.
Scheme 2: A3-coupling reaction catalyzed by polystyrene-supported NHC–silver halides.
Figure 1: Various NHC–Ag(I) complexes used as catalysts for A3-coupling.
Scheme 3: Proposed reaction mechanism for NHC–AgCl catalyzed A3-coupling reactions.
Scheme 4: Liu’s synthesis of pyrrole-2-carboxaldehydes 4.
Scheme 5: Proposed reaction mechanism for Liu’s synthesis of pyrrole-2-carboxaldehydes 4.
Scheme 6: Gold-catalyzed synthesis of propargylamines 1.
Scheme 7: A3-coupling catalyzed by phosphinamidic Au(III) metallacycle 6.
Scheme 8: Gold-catalyzed KA2-coupling.
Scheme 9: A3-coupling applied to aldehyde-containing oligosaccharides 8.
Scheme 10: A3-MCR for the preparation of propargylamine-substituted indoles 9.
Scheme 11: A3-coupling interceded synthesis of furans 12.
Scheme 12: A3/KA2-coupling mediated synthesis of functionalized dihydropyrazoles 13 and polycyclic dihydropyra...
Scheme 13: Au(I)-catalyzed entry to cyclic carbamimidates 17 via an A3-coupling-type approach.
Scheme 14: Proposed reaction mechanism for the Au(I)-catalyzed synthesis of cyclic carbamimidates 17.
Figure 2: Chiral trans-1-diphenylphosphino-2-aminocyclohexane–Au(I) complex 20.
Scheme 15: A3-coupling-type synthesis of oxazoles 21 catalyzed by Au(III)–salen complex.
Scheme 16: Proposed reaction mechanism for the synthesis of oxazoles 21.
Scheme 17: Synthesis of propargyl ethyl ethers 24 by an A3-coupling-type reaction.
Scheme 18: General mechanism of Ag(I)-catalyzed MCRs of 2-alkynylbenzaldehydes, amines and nucleophiles.
Scheme 19: General synthetic pathway to 1,3-disubstituted-1,2-dihydroisoquinolines.
Scheme 20: Synthesis of 1,3-disubstituted-1,2-dihydroisoquinolines 29.
Scheme 21: Synthesis of 1,3-disubstituted-1,2-dihydroisoquinolines 35 and 36.
Scheme 22: Rh(II)/Ag(I) co-catalyzed synthesis of 1,3-disubstituted-1,2-dihydroisoquinolines 40.
Scheme 23: General synthetic pathway to 2-amino-1,2-dihydroquinolines.
Scheme 24: Synthesis of 2-amino-1,2-dihydroquinolines 47.
Scheme 25: Synthesis of tricyclic H-pyrazolo[5,1-a]isoquinoline 48.
Scheme 26: Synthesis of tricyclic H-pyrazolo[5,1-a]isoquinolines 48.
Scheme 27: Cu(II)/Ag(I) catalyzed synthesis of H-pyrazolo[5,1-a]isoquinolines 48.
Scheme 28: Synthesis of 2-aminopyrazolo[5,1-a]isoquinolines 53.
Scheme 29: Synthesis of 1-(isoquinolin-1-yl)guanidines 55.
Scheme 30: Ag(I)/Cu(I) catalyzed synthesis of 2-amino-H-pyrazolo[5,1-a]isoquinolines 58.
Scheme 31: Ag(I)/Ni(II) co-catalyzed synthesis of 3,4-dihydro-1H-pyridazino[6,1-a]isoquinoline-1,1-dicarboxyla...
Scheme 32: Ag(I) promoted activation of the α-carbon atom of the isocyanide group.
Scheme 33: Synthesis of dihydroimidazoles 65.
Scheme 34: Synthesis of oxazoles 68.
Scheme 35: Stereoselective synthesis of chiral butenolides 71.
Scheme 36: Proposed reaction mechanism for the synthesis of butenolides 71.
Scheme 37: Stereoselective three-component approach to pirrolidines 77 by means of a chiral auxiliary.
Scheme 38: Stereoselective three-component approach to pyrrolidines 81 and 82 by means of a chiral catalyst.
Scheme 39: Synthesis of substituted five-membered carbocyles 86.
Scheme 40: Synthesis of regioisomeric arylnaphthalene lactones.
Scheme 41: Enantioselective synthesis of spiroacetals 96 by Fañanás and Rodríguez [105].
Scheme 42: Enantioselective synthesis of spiroacetals 101 by Gong [106].
Scheme 43: Synthesis of polyfunctionalized fused bicyclic ketals 103 and bridged tricyclic ketals 104.
Scheme 44: Proposed reaction mechanism for the synthesis of ketals 103 and 104.
Scheme 45: Synthesis of β-alkoxyketones 108.
Scheme 46: Synthesis of N-methyl-1,4-dihydropyridines 112.
Scheme 47: Synthesis of tetrahydrocarbazoles 115–117.
Scheme 48: Plausible reaction mechanism for the synthesis of tetrahydrocarbazoles 115–117.
Scheme 49: Carboamination, carboalkoxylation and carbolactonization of terminal alkenes.
Scheme 50: Oxyarylation of alkenes with arylboronic acids and Selectfluor as reoxidant.
Scheme 51: Proposed reaction mechanism for oxyarylation of alkenes.
Scheme 52: Oxyarylation of alkenes with arylsilanes and Selectfluor as reoxidant.
Scheme 53: Oxyarylation of alkenes with arylsilanes and IBA as reoxidant.
Beilstein J. Org. Chem. 2014, 10, 405–424, doi:10.3762/bjoc.10.38
Graphical Abstract
Figure 1: Analysis of the literature on aromatic nitration over the last 50 years. Numbers next to each nitra...
Figure 2: Schematic of a typical experimental setup for aromatic nitration. The circular segment shown inside...
Scheme 1: Nitration of substituted pyrazole-5-carboxylic acid 1. T = 90 °C, residence time = 35 min, yield: 7...
Scheme 2: Nitration of 2-methylindole (4). T = 3 °C, residence time = 48 s, yield: 70%. [27].
Scheme 3: Nitration of pyridine-N-oxide (6), T = 120 °C, residence time = 80 min, yield: 78% (72% in the flas...
Scheme 4: Nitration of toluene (8). Method 1: H2SO4/HNO3, T = 65 °C, residence time = 15 min. Method 2: Ac2O/H...
Figure 3: Graphical presentation of a microreactor used for double nitration and the schematic of the experim...
Scheme 5: Nitration of 2-amino-6-chloro-4-pyrimidinol (14) [25].
Scheme 6: Nitration of benzaldehyde (16) [35].
Scheme 7: Nitration of salicylic acid (19) [30].
Scheme 8: Nitration of phenol (22) yielding mono-nitro isomers 23 and 24 as main products, hydroquinone (25),...
Scheme 9: Synthesis of 3-methyl-4-nitropyrazole (29) and 3,5-dimethyl-4-nitropyrazole (31) [31].
Figure 4: Photograph of the experimental setup for the synthesis of alkyl-nitropyrazoles. IMM’s SIMM-V2 micro...
Scheme 10: Nitration of chlorobenzene (33) [23].
Figure 5: Continuous flow nitration of chlorobenzene (33) with nitric acid in a sequence of continuously stir...
Scheme 11: Nitration of 2-isopropoxybenzaldehyde (36) by using red fuming nitric acid [37].
Figure 6: Silicon-glass microreactor by Knapkiewicz et al. [37]. (A) Layout of the microreactor with a built-in m...
Scheme 12: Synthesis of nitropyridine (40) [39].
Figure 7: Schematic of the experimental setup involving a pressure based charging system [39]. Reproduced with pe...
Scheme 13: Nitration of p-difluorobenzene (42) [40].
Figure 8: Schematic of the flow reactor arrangement. Reproduced with permission from [40]. Copyright 2013 The Ame...
Scheme 14: Nitration of naphthalene (47) [34].
Figure 9: Structure of the microreactor. (A) Top view (1, 2 – inlets, 3 – mixing points, 4 – outlet). (B) Lat...
Scheme 15: Nitration of 2-nitropropane (52) [38].
Figure 10: Schematic of the continuous nitration system reported in CN103044261A [56].
Beilstein J. Org. Chem. 2014, 10, 287–292, doi:10.3762/bjoc.10.25
Graphical Abstract
Figure 1: Some DHPMs-based lead compounds.
Scheme 1: Regioselective 1,3-thiazines and DHPMs via aldehydes, ureas/thioureas and alkynes.
Scheme 2: Synthesis of enamino ester intermediate and its transformation to DHPM.
Scheme 3: Proposed reaction mechanism.
Beilstein J. Org. Chem. 2014, 10, 224–236, doi:10.3762/bjoc.10.18
Graphical Abstract
Figure 1: Thiourea, squaramide, P-triamide and cyclodiphosphazane with computed distances between H-atoms.
Figure 2: Urea, squaramide, P-triamide and cyclodiphosphazane coordinated to nitrobenzene, with the computed ...
Scheme 1: Chiral PV-amide catalysts based on BINOL and chinchona backbones.
Scheme 2: Exclusive formation of the mono- and trisubstituted product from thiophosphoryl chloride and anilin...
Figure 3: X-ray structure of 6-dimer. The hydrogen atoms are omitted for clarity, except at all nitrogens.
Figure 4: X-ray structure of 7a-dimer. The hydrogen atoms are omitted for clarity, except at all nitrogens.
Scheme 3: Synthesis of chiral cyclodiphosphazane catalysts 14a/b, 15 and 16.
Figure 5: X-ray structure of 14a. The hydrogen atoms are omitted for clarity, except at nitrogen.
Figure 6: 31P{1H} NMR spectrum in CDCl3 at rt showing C2 symmetry of 14a at rt.
Figure 7: X-ray structure of 15. The hydrogen atoms are omitted for clarity, except at nitrogen.
Figure 8: X-ray structure of 16. The hydrogen atoms are omitted for clarity, except at nitrogen.
Figure 9: Enantiodetermining transition states TS-14a/TS-14b arising from the addition of 2-hydroxynapthoquin...
Beilstein J. Org. Chem. 2014, 10, 34–114, doi:10.3762/bjoc.10.6
Graphical Abstract
Figure 1: Five and six-membered cyclic peroxides.
Figure 2: Artemisinin and semi-synthetic derivatives.
Scheme 1: Synthesis of 3-hydroxy-1,2-dioxolanes 3a–c.
Scheme 2: Synthesis of dioxolane 6.
Scheme 3: Photooxygenation of oxazolidines 7a–d with formation of spiro-fused oxazolidine-containing dioxolan...
Scheme 4: Oxidation of cyclopropanes 10a–e and 11a–e with preparation of 1,2-dioxolanes 12a–e.
Scheme 5: VO(acac)2-catalyzed oxidation of silylated bicycloalkanols 13a–c.
Scheme 6: Mn(II)-catalyzed oxidation of cyclopropanols 15a–g.
Scheme 7: Oxidation of aminocyclopropanes 20a–c.
Scheme 8: Synthesis of aminodioxolanes 24.
Figure 3: Trifluoromethyl-containing dioxolane 25.
Scheme 9: Synthesis of 1,2-dioxolanes 27a–e by the oxidation of cyclopropanes 26a–e.
Scheme 10: Photoinduced oxidation of methylenecyclopropanes 28.
Scheme 11: Irradiation-mediated oxidation.
Scheme 12: Application of diazene 34 for dioxolane synthesis.
Scheme 13: Mn(OAc)3-catalyzed cooxidation of arylacetylenes 37a–h and acetylacetone with atmospheric oxygen.
Scheme 14: Peroxidation of (2-vinylcyclopropyl)benzene (40).
Scheme 15: Peroxidation of 1,4-dienes 43a,b.
Scheme 16: Peroxidation of 1,5-dienes 46.
Scheme 17: Peroxidation of oxetanes 53a,b.
Scheme 18: Peroxidation of 1,6-diene 56.
Scheme 19: Synthesis of 3-alkoxy-1,2-dioxolanes 62a,b.
Scheme 20: Synthesis of spiro-bis(1,2-dioxolane) 66.
Scheme 21: Synthesis of dispiro-1,2-dioxolanes 68, 70, 71.
Scheme 22: Synthesis of spirohydroperoxydioxolanes 75a,b.
Scheme 23: Synthesis of spirohydroperoxydioxolane 77 and dihydroperoxydioxolane 79.
Scheme 24: Ozonolysis of azepino[4,5-b]indole 80.
Scheme 25: SnCl4-mediated fragmentation of ozonides 84a–l in the presence of allyltrimethylsilane.
Scheme 26: SnCl4-mediated fragmentation of bicyclic ozonide 84m in the presence of allyltrimethylsilane.
Scheme 27: MCl4-mediated fragmentation of alkoxyhydroperoxides 96 in the presence of allyltrimethylsilane.
Scheme 28: SnCl4-catalyzed reaction of monotriethylsilylperoxyacetal 108 with alkene 109.
Scheme 29: SnCl4-catalyzed reaction of triethylsilylperoxyacetals 111 with alkenes.
Scheme 30: Desilylation of tert-butyldimethylsilylperoxy ketones 131a,b followed by cyclization.
Scheme 31: Deprotection of peroxide 133 followed by cyclization.
Scheme 32: Asymmetric peroxidation of methyl vinyl ketones 137a–e.
Scheme 33: Et2NH-catalyzed intramolecular cyclization.
Scheme 34: Synthesis of oxodioxolanes 143a–j.
Scheme 35: Haloperoxidation accompanied by intramolecular ring closure.
Scheme 36: Oxidation of triterpenes 149a–d with Na2Cr2O7/N-hydroxysuccinimide.
Scheme 37: Curtius and Wolff rearrangements to form 1,2-dioxolane ring-retaining products.
Scheme 38: Oxidative desilylation of peroxide 124.
Scheme 39: Synthesis of dioxolane 158, a compound containing the aminoquinoline antimalarial pharmacophore.
Scheme 40: Diastereomers of plakinic acid A, 162a and 162b.
Scheme 41: Ozonolysis of alkenes.
Scheme 42: Cross-ozonolysis of alkenes 166 with carbonyl compounds.
Scheme 43: Ozonolysis of the bicyclic cyclohexenone 168.
Scheme 44: Cross-ozonolysis of enol ethers 172a,b with cyclohexanone.
Scheme 45: Griesbaum co-ozonolysis.
Scheme 46: Reactions of aryloxiranes 177a,b with oxygen.
Scheme 47: Intramolecular formation of 1,2,4-trioxolane 180.
Scheme 48: Formation of 1,2,4-trioxolane 180 by the reaction of 1,5-ketoacetal 181 with H2O2.
Scheme 49: 1,2,4-Trioxolane 186 with tetrazole fragment.
Scheme 50: 1,2,4-Trioxolane 188 with a pyridine fragment.
Scheme 51: 1,2,4-Trioxolane 189 with pyrimidine fragment.
Scheme 52: Synthesis of aminoquinoline-containing 1,2,4-trioxalane 191.
Scheme 53: Synthesis of arterolane.
Scheme 54: Oxidation of diarylheptadienes 197a–c with singlet oxygen.
Scheme 55: Synthesis of hexacyclinol peroxide 200.
Scheme 56: Oxidation of enone 201 and enenitrile 203 with singlet oxygen.
Scheme 57: Synthesis of 1,2-dioxanes 207 by oxidative coupling of carbonyl compounds 206 and alkenes 205.
Scheme 58: 1,2-Dioxanes 209 synthesis by co-oxidation of 1,5-dienes 208 and thiols.
Scheme 59: Synthesis of bicyclic 1,2-dioxanes 212 with aryl substituents.
Scheme 60: Isayama–Mukaiyama peroxysilylation of 1,5-dienes 213 followed by desilylation under acidic conditio...
Scheme 61: Synthesis of bicycle 218 with an 1,2-dioxane ring.
Scheme 62: Intramolecular cyclization with an oxirane-ring opening.
Scheme 63: Inramolecular cyclization with the oxetane-ring opening.
Scheme 64: Intramolecular cyclization with the attack on a keto group.
Scheme 65: Peroxidation of the carbonyl group in unsaturated ketones 228 followed by cyclization of hydroperox...
Scheme 66: CsOH and Et2NH-catalyzed cyclization.
Scheme 67: Preparation of peroxyplakoric acid methyl ethers A and D.
Scheme 68: Hg(OAc)2 in 1,2-dioxane synthesis.
Scheme 69: Reaction of 1,4-diketones 242 with hydrogen peroxide.
Scheme 70: Inramolecular cyclization with oxetane-ring opening.
Scheme 71: Inramolecular cyclization with MsO fragment substitution.
Scheme 72: Synthesis of 1,2-dioxane 255a, a structurally similar compound to natural peroxyplakoric acids.
Scheme 73: Synthesis of 1,2-dioxanes based on the intramolecular cyclization of hydroperoxides containing C=C ...
Scheme 74: Use of BCIH in the intramolecular cyclization.
Scheme 75: Palladium-catalyzed cyclization of δ-unsaturated hydroperoxides 271a–e.
Scheme 76: Intramolecular cyclization of unsaturated peroxyacetals 273a–d.
Scheme 77: Allyltrimethylsilane in the synthesis of 1,2-dioxanes 276a–d.
Scheme 78: Intramolecular cyclization using the electrophilic center of the peroxycarbenium ion 279.
Scheme 79: Synthesis of bicyclic 1,2-dioxanes.
Scheme 80: Preparation of 1,2-dioxane 286.
Scheme 81: Di(tert-butyl)peroxalate-initiated radical cyclization of unsaturated hydroperoxide 287.
Scheme 82: Oxidation of 1,4-betaines 291a–d.
Scheme 83: Synthesis of aminoquinoline-containing 1,2-dioxane 294.
Scheme 84: Synthesis of the sulfonyl-containing 1,2-dioxane.
Scheme 85: Synthesis of the amido-containing 1,2-dioxane 301.
Scheme 86: Reaction of singlet oxygen with the 1,3-diene system 302.
Scheme 87: Synthesis of (+)-premnalane А and 8-epi-premnalane A.
Scheme 88: Synthesis of the diazo group containing 1,2-dioxenes 309a–e.
Figure 4: Plakortolide Е.
Scheme 89: Synthesis of 6-epiplakortolide Е.
Scheme 90: Application of Bu3SnH for the preparation of tetrahydrofuran-containing bicyclic peroxides 318a,b.
Scheme 91: Application of Bu3SnH for the preparation of lactone-containing bicyclic peroxides 320a–f.
Scheme 92: Dihydroxylation of the double bond in the 1,2-dioxene ring 321 with OsO4.
Scheme 93: Epoxidation of 1,2-dioxenes 324.
Scheme 94: Cyclopropanation of the double bond in endoperoxides 327.
Scheme 95: Preparation of pyridazine-containing bicyclic endoperoxides 334a–c.
Scheme 96: Synthesis of 1,2,4-trioxanes 337 by the hydroperoxidation of unsaturated alcohols 335 with 1O2 and ...
Scheme 97: Synthesis of sulfur-containing 1,2,4-trioxanes 339.
Scheme 98: BF3·Et2O-catalyzed synthesis of the 1,2,4-trioxanes 342a–g.
Scheme 99: Photooxidation of enol ethers or vinyl sulfides 343.
Scheme 100: Synthesis of tricyclic peroxide 346.
Scheme 101: Reaction of endoperoxides 348a,b derived from cyclohexadienes 347a,b with 1,4-cyclohexanedione.
Scheme 102: [4 + 2]-Cycloaddition of singlet oxygen to 2Н-pyrans 350.
Scheme 103: Synthesis of 1,2,4-trioxanes 354 using peroxysilylation stage.
Scheme 104: Epoxide-ring opening in 355 with H2O2 followed by the condensation of hydroxy hydroperoxides 356 wi...
Scheme 105: Peroxidation of unsaturated ketones 358 with the H2O2/CF3COOH/H2SO4 system.
Scheme 106: Synthesis of 1,2,4-trioxanes 362 through Et2NH-catalyzed intramolecular cyclization.
Scheme 107: Reduction of the double bond in tricyclic peroxides 363.
Scheme 108: Horner–Wadsworth–Emmons reaction in the presence of peroxide group.
Scheme 109: Reduction of ester group by LiBH4 in the presence of 1,2,4-trioxane moiety.
Scheme 110: Reductive amination of keto-containing 1,2,4-trioxane 370.
Scheme 111: Reductive amination of keto-containing 1,2,4-trioxane and a Fe-containing moiety.
Scheme 112: Acid-catalyzed reactions of Н2О2 with ketones and aldehydes 374.
Scheme 113: Cyclocondensation of carbonyl compounds 376a–d using Me3SiOOSiMe3/CF3SO3SiMe3.
Scheme 114: Peroxidation of 4-methylcyclohexanone (378).
Scheme 115: Synthesis of symmetrical tetraoxanes 382a,b from aldehydes 381a,b.
Scheme 116: Synthesis of unsymmetrical tetraoxanes using of MeReO3.
Scheme 117: Synthesis of symmetrical tetraoxanes using of MeReO3.
Scheme 118: Synthesis of symmetrical tetraoxanes using of MeReO3.
Scheme 119: MeReO3 in the synthesis of symmetrical tetraoxanes with the use of aldehydes.
Scheme 120: Preparation of unsymmmetrical 1,2,4,5-tetraoxanes with high antimalarial activity.
Scheme 121: Re2O7-Catalyzed synthesis of tetraoxanes 398.
Scheme 122: H2SO4-Catalyzed synthesis of steroidal tetraoxanes 401.
Scheme 123: HBF4-Catalyzed condensation of bishydroperoxide 402 with 1,4-cyclohexanedione.
Scheme 124: BF3·Et2O-Catalyzed reaction of gem-bishydroperoxides 404 with enol ethers 405 and acetals 406.
Scheme 125: HBF4-Catalyzed cyclocondensation of bishydroperoxide 410 with ketones.
Scheme 126: Synthesis of symmetrical and unsymmetrical tetraoxanes 413 from benzaldehydes 412.
Scheme 127: Synthesis of bridged 1,2,4,5-tetraoxanes 415a–l from β-diketones 414a–l and H2O2.
Scheme 128: Dimerization of zwitterions 417.
Scheme 129: Ozonolysis of verbenone 419.
Scheme 130: Ozonolysis of O-methyl oxime 424.
Scheme 131: Peroxidation of 1,1,1-trifluorododecan-2-one 426 with oxone.
Scheme 132: Intramolecular cyclization of dialdehyde 428 with H2O2.
Scheme 133: Tetraoxanes 433–435 as by-products in peroxidation of ketals 430–432.
Scheme 134: Transformation of triperoxide 436 in diperoxide 437.
Scheme 135: Preparation and structural modifications of tetraoxanes.
Scheme 136: Structural modifications of steroidal tetraoxanes.
Scheme 137: Synthesis of 1,2,4,5-tetraoxane 454 containing the fluorescent moiety.
Scheme 138: Synthesis of tetraoxane 458 (RKA182).
Beilstein J. Org. Chem. 2013, 9, 2846–2851, doi:10.3762/bjoc.9.320
Graphical Abstract
Figure 1: X-ray crystal structure of 4a.
Scheme 1: Possible mechanism.
Figure 2: Scope of the enantioselective reaction. Reaction conditions: 5a (10 mol %, 0.02 mmol), 1 (0.2 mmol)...
Beilstein J. Org. Chem. 2013, 9, 2586–2614, doi:10.3762/bjoc.9.294
Graphical Abstract
Figure 1: Elementary steps in the gold-catalyzed nucleophilic addition to olefins.
Figure 2: Different approaches for the gold-catalyzed manipulation of inactivated alkenes.
Figure 3: Computed mechanistic cycle for the gold-catalyzed alkoxylation of ethylene with PhOH.
Scheme 1: [Au(I)]-catalyzed addition of phenols and carboxylic acids to alkenes.
Scheme 2: [Au(III)] catalyzed annulations of phenols and naphthols with dienes.
Scheme 3: [Au(III)]-catalyzed addition of aliphatic alcohols to alkenes.
Scheme 4: [Au(III)]-catalyzed carboalkoxylation of alkenes with dimethyl acetals 6.
Figure 4: Postulated mechanism for the [Au(I)]-catalyzed hydroamination of olefins.
Scheme 5: Isolation and reactivity of alkyl gold intermediates in the intramolecular hydroamination of alkene...
Scheme 6: [Au(I)]-catalyzed intermolecular hydroamination of dienes.
Scheme 7: Intramolecular [Au(I)]-catalyzed hydroamination of alkenes with carbamates.
Scheme 8: [Au(I)]-catalyzed inter- as well as intramolecular addition of sulfonamides to isolated alkenes.
Scheme 9: Intramolecular hydroamination of N-alkenylureas catalyzed by gold(I) carbene complex.
Scheme 10: Enantioselective hydroamination of alkenyl ureas with biphenyl tropos ligand and chiral silver phos...
Scheme 11: Intramolecular [Au(I)]-catalyzed hydroamination of N-allyl-N’-aryl ureas. (PNP = pNO2-C6H4, PMP = p...
Scheme 12: [Au(I)]-catalyzed hydroamination of alkenes with ammonium salts.
Scheme 13: Enantioselective [Au(I)]-catalyzed intermolecular hydroamination of alkenes with cyclic ureas.
Scheme 14: Mechanistic proposal for the cooperative [Au(I)]/menthol catalysis for the enantioselective intramo...
Scheme 15: [Au(III)]-catalyzed addition of 1,3-diketones to alkenes.
Scheme 16: [Au(I)]-catalyzed intramolecular addition of β-keto amides to alkenes.
Scheme 17: Intermolecular [Au(I)]-catalyzed addition of indoles to alkenes.
Scheme 18: Intermolecular [Au(III)]-catalyzed hydroarylation of alkenes with benzene derivatives and thiophene....
Scheme 19: a) Intramolecular [Au(III)]-catalyzed hydroarylation of alkenes. b) A SEAr-type mechanism was hypot...
Scheme 20: Intramolecular [Au(I)]-catalyzed hydroalkylation of alkenes with simple ketones.
Scheme 21: Proposed reaction mechanism for the intramolecular [Au(I)]-catalyzed hydroalkylation of alkenes wit...
Scheme 22: Tandem Michael addition/hydroalkylation catalyzed by [Au(I)] and [Ag(I)] salts.
Scheme 23: Intramolecular [Au(I)]-catalyzed tandem migration/[2 + 2] cycloaddition of 1,7-enyne benzoates.
Scheme 24: Intramolecular [Au(I)]-catalyzed cyclopropanation of alkenes.
Scheme 25: Stereospecificity in [Au(I)]-catalyzed hydroalkoxylation of allylic alcohols.
Scheme 26: Mechanistic investigation on the intramolecular [Au(I)]-catalyzed hydroalkoxylation of allylic alco...
Scheme 27: Mechanistic investigation on the intramolecular enantioselective [Au(I)]-catalyzed alkylation of in...
Scheme 28: Synthesis of (+)-isoaltholactone via stereospecific intramolecular [Au(I)]-catalyzed alkoxylation o...
Scheme 29: Intramolecular enantioselective dehydrative amination of allylic alcohols catalyzed by chiral [Au(I...
Scheme 30: Enantioselective intramolecular hydroalkylation of allylic alcohols with aldehydes catalyzed by 20c...
Scheme 31: Gold-catalyzed intramolecular diamination of alkenes.
Scheme 32: Gold-catalyzed aminooxygenation and aminoarylation of alkenes.
Scheme 33: Gold-catalyzed carboamination, carboalkoxylation and carbolactonization of terminal alkenes with ar...
Scheme 34: Synthesis of tricyclic indolines via gold-catalyzed formal [3 + 2] cycloaddition.
Scheme 35: Gold(I) catalyzed aminoarylation of terminal alkenes in presence of Selectfluor [dppm = bis(dipheny...
Scheme 36: Mechanistic investigation on the aminoarylation of terminal alkenes by bimetallic gold(I) catalysis...
Scheme 37: Proposed mechanism for the aminoarylation of alkenes via [Au(I)-Au(I)]/[Au(II)-Au(II)] redox cataly...
Scheme 38: Oxyarylation of terminal olefins via redox gold catalysis.
Scheme 39: a) Intramolecular gold-catalyzed oxidative coupling reactions with aryltrimethylsilanes. b) Oxyaryl...
Scheme 40: Oxy- and amino-arylation of alkenes by [Au(I)]/[Au(III)] photoredox catalysis.
Beilstein J. Org. Chem. 2013, 9, 2378–2386, doi:10.3762/bjoc.9.274
Beilstein J. Org. Chem. 2013, 9, 2265–2319, doi:10.3762/bjoc.9.265
Graphical Abstract
Scheme 1: Scaled industrial processes for the synthesis of simple pyridines.
Scheme 2: Synthesis of nicotinic acid from 2-methyl-5-ethylpyridine (1.11).
Scheme 3: Synthesis of 3-picoline and nicotinic acid.
Scheme 4: Synthesis of 3-picoline from 2-methylglutarodinitrile 1.19.
Scheme 5: Picoline-based synthesis of clarinex (no yields reported).
Scheme 6: Mode of action of proton-pump inhibitors and structures of the API’s.
Scheme 7: Hantzsch-like route towards the pyridine rings in common proton pump inhibitors.
Figure 1: Structures of rosiglitazone (1.40) and pioglitazone (1.41).
Scheme 8: Synthesis of rosiglitazone.
Scheme 9: Syntheses of 2-pyridones.
Scheme 10: Synthesis and mechanism of 2-pyrone from malic acid.
Scheme 11: Polymer-assisted synthesis of rosiglitazone.
Scheme 12: Synthesis of pioglitazone.
Scheme 13: Meerwein arylation reaction towards pioglitazone.
Scheme 14: Route towards pioglitazone utilising tyrosine.
Scheme 15: Route towards pioglitazone via Darzens ester formation.
Scheme 16: Syntheses of the thiazolidinedione moiety.
Scheme 17: Synthesis of etoricoxib utilising Negishi and Stille cross-coupling reactions.
Scheme 18: Synthesis of etoricoxib via vinamidinium condensation.
Figure 2: Structures of nalidixic acid, levofloxacin and moxifloxacin.
Scheme 19: Synthesis of moxifloxacin.
Scheme 20: Synthesis of (S,S)-2,8-diazabicyclo[4.3.0]nonane 1.105.
Scheme 21: Synthesis of levofloxacin.
Scheme 22: Alternative approach to the levofloxacin core 1.125.
Figure 3: Structures of nifedipine, amlodipine and clevidipine.
Scheme 23: Mg3N2-mediated synthesis of nifedipine.
Scheme 24: Synthesis of rac-amlodipine as besylate salt.
Scheme 25: Aza Diels–Alder approach towards amlodipine.
Scheme 26: Routes towards clevidipine.
Figure 4: Examples of piperidine containing drugs.
Figure 5: Discovery of tiagabine based on early leads.
Scheme 27: Synthetic sequences to tiagabine.
Figure 6: Structures of solifenacin (2.57) and muscarine (2.58).
Scheme 28: Enantioselective synthesis of solifenacin.
Figure 7: Structures of DPP-4 inhibitors of the gliptin-type.
Scheme 29: Formation of inactive diketopiperazines from cis-rotameric precursors.
Figure 8: Co-crystal structure of carmegliptin bound in the human DPP-4 active site (PDB 3kwf).
Scheme 30: Improved route to carmegliptin.
Figure 9: Structures of lamivudine and zidovudine.
Scheme 31: Typical routes accessing uracil, thymine and cytosine.
Scheme 32: Coupling between pyrimidones and riboses via the Vorbrüggen nucleosidation.
Scheme 33: Synthesis of lamivudine.
Scheme 34: Synthesis of raltegravir.
Scheme 35: Mechanistic studies on the formation of 3.22.
Figure 10: Structures of selected pyrimidine containing drugs.
Scheme 36: General preparation of pyrimidines and dihydropyrimidones.
Scheme 37: Synthesis of imatinib.
Scheme 38: Flow synthesis of imatinib.
Scheme 39: Syntheses of erlotinib.
Scheme 40: Synthesis of erlotinib proceeding via Dimroth rearrangement.
Scheme 41: Synthesis of lapatinib.
Scheme 42: Synthesis of rosuvastatin.
Scheme 43: Alternative preparation of the key aldehyde towards rosuvastatin.
Figure 11: Structure comparison between nicotinic acetylcholine receptor agonists.
Scheme 44: Syntheses of varenicline and its key building block 4.5.
Scheme 45: Synthetic access to eszopiclone and brimonidine via quinoxaline intermediates.
Figure 12: Bortezomib bound in an active site of the yeast 20S proteasome ([114], pdb 2F16).
Scheme 46: Asymmetric synthesis of bortezomib.
Figure 13: Structures of some prominent piperazine containing drugs.
Figure 14: Structural comparison between the core of aplaviroc (4.35) and a type-1 β-turn (4.36).
Scheme 47: Examplary synthesis of an aplaviroc analogue via the Ugi-MCR.
Scheme 48: Syntheses of azelastine (5.1).
Figure 15: Structures of captopril, enalapril and cilazapril.
Scheme 49: Synthesis of cilazapril.
Figure 16: Structures of lamotrigine, ceftriaxone and azapropazone.
Scheme 50: Synthesis of lamotrigine.
Scheme 51: Alternative synthesis of lamotrigine (no yields reported).
Figure 17: Structural comparison between imiquimod and the related adenosine nucleoside.
Scheme 52: Conventional synthesis of imiquimod (no yields reported).
Scheme 53: Synthesis of imiquimod.
Scheme 54: Synthesis of imiquimod via tetrazole formation (not all yields reported).
Figure 18: Structures of various anti HIV-medications.
Scheme 55: Synthesis of abacavir.
Figure 19: Structures of diazepam compared to modern replacements.
Scheme 56: Synthesis of ocinaplon.
Scheme 57: Access to zaleplon and indiplon.
Scheme 58: Different routes towards the required N-methylpyrazole 6.65 of sildenafil.
Scheme 59: Polymer-supported reagents in the synthesis of key aminopyrazole 6.72.
Scheme 60: Early synthetic route to sildenafil.
Scheme 61: Convergent preparations of sildenafil.
Figure 20: Comparison of the structures of sildenafil, tadalafil and vardenafil.
Scheme 62: Short route to imidazotriazinones.
Scheme 63: Alternative route towards vardenafils core imidazotriazinone (6.95).
Scheme 64: Bayer’s approach to the vardenafil core.
Scheme 65: Large scale synthesis of vardenafil.
Scheme 66: Mode of action of temozolomide (6.105) as methylating agent.
Scheme 67: Different routes to temozolomide.
Scheme 68: Safer route towards temozolomide.
Figure 21: Some unreported heterocyclic scaffolds in top market drugs.
Beilstein J. Org. Chem. 2013, 9, 1843–1852, doi:10.3762/bjoc.9.215
Graphical Abstract
Figure 1: (a) Flow cell and (b) Raman interface used in the present study.
Scheme 1: The reaction between salicylaldehyde and ethyl acetoacetate to form 3-acetyl coumarin (1).
Figure 2: The Raman spectrum of 3-acetylcoumarin (1) generated using Gaussian 09 [40] at the B3LYP/6-31g(d) level...
Figure 3: Monitoring an aliquot of 3-acetyl coumarin (1) as it passes through the flow cell (scan time = 15 s...
Figure 4: Monitoring the conversion of salicylaldehyde and ethyl acetoacetate to 3-acetylcoumarin (1) across ...
Figure 5: Plot of Raman intensity of the peak arising at 1608 cm-1 vs concentration of 3-acetyl coumarin (1),...
Scheme 2: The Knoevenagel condensation of benzaldehyde and ethyl acetoacetate to yield (Z)-ethyl 2-benzyliden...
Figure 6: Monitoring the conversion of benzaldehyde and ethyl acetoacetate to (Z)-ethyl 2-benzylidene-3-oxobu...
Scheme 3: Claisen-Schmidt condensation of benzaldehyde with acetophenone to yield chalcone, 3a.
Figure 7: Monitoring the conversion of benzaldehyde with acetophenone to chalcone, 3a, across a range of reac...
Scheme 4: The Biginelli cyclocondensation of benzaldehyde, ethyl acetoacetate, and urea to yield 5-ethoxycarb...
Figure 8: Monitoring the conversion of benzaldehyde, ethyl acetoacetate, and urea to 5-ethoxycarbonyl-6-methy...
Beilstein J. Org. Chem. 2013, 9, 1677–1695, doi:10.3762/bjoc.9.192
Graphical Abstract
Figure 1: The catalyzed enantioselective desymmetrization.
Figure 2: Cinchona alkaloid-derived catalysts OC-1 to OC-11.
Scheme 1: The enantioselective desymmetrization of meso-aziridines in the presence of selected Cinchona alkal...
Figure 3: Cinchona alkaloid-derived catalysts OC-12 to OC-19.
Scheme 2: The enantioselective ring-opening of aziridines in the presence of OC-16.
Scheme 3: OC-16 catalyzed enantioselective ring-opening of aziridines.
Figure 4: The chiral phosphoric acids catalysts OC-20 and OC-21.
Scheme 4: OC-20 and OC-21 catalyzed enantioselective desymmetrization of meso-aziridines.
Figure 5: The proposed mechanism for chiral phosphorous acid-induced enantioselctive desymmetrization of meso...
Scheme 5: OC-21 catalyzed enantioselective desymmetrization of meso-aziridines by Me3SiSPh.
Scheme 6: OC-21 catalyzed the enantioselective desymmetrization of meso-aziridines by Me3SiSePh/PhSeH.
Figure 6: L-Proline and its derivatives OC-22 to OC-27.
Scheme 7: OC-23 catalyzed enantioselective desymmetrization of meso-aziridines.
Figure 7: Proposed bifunctional mode of action of OC-23.
Figure 8: The chiral thioureas OC-28 to OC-44 for the desymmetrization of meso-aziridines.
Scheme 8: Desymmetrization of meso-aziridines with OC-41.
Figure 9: The chiral guanidines (OC-45 to OC-48).
Scheme 9: OC-46 catalyzed desymmetrization of meso-aziridines by arylthiols.
Scheme 10: Desymmetrization of cis-aziridine-2,3-dicarboxylate.
Figure 10: The proposed activation mode of OC-46.
Scheme 11: The enantioselective desymmetrization of meso-aziridines by amine/CS2 in the presence of OC-46.
Figure 11: The chiral 1,2,3-triazolium chlorides OC-49 to OC-55.
Scheme 12: The enantioselective desymmetrization of meso-aziridines by Me3SiX (X = Cl or Br) in the presence o...
Figure 12: Early organocatalysts for enantioselective desymmetrization of meso-epoxides.
Scheme 13: Attempts of enantioselective desymmetrization of meso-epoxides in the presence of OC-58 or OC-60.
Scheme 14: The enantioselective desymmetrization of a meso-epoxide containing one P atom.
Figure 13: Some chiral phosphoramide and chiral phosphine oxides.
Scheme 15: OC-62 catalyzed enantioselective desymmetrization of meso-epoxides by SiCl4.
Figure 14: The proposed mechanism of the chiral HMPA-catalyzed desymmetrization of meso-epoxides.
Scheme 16: The enantioselective desymmetrization of meso-epoxides in the presence of OC-63.
Figure 15: The Chiral phosphine oxides (OC-70 to OC-77) based on an allene backbone.
Scheme 17: OC-73 catalyzed enantioselective desymmetrization of meso-epoxides by SiCl4.
Figure 16: Chiral pyridine N-oxides used in enantioselective desymmetrization of meso-epoxides.
Scheme 18: Catalyzed enantioselective desymmetrization of meso-epoxides in the presence of OC-80 or OC-82.
Figure 17: Chiral pyridine N-oxides OC-85 to OC-94.
Scheme 19: Enantioselective desymmetrization of cis-stilbene oxide by using OC-85 to OC-92 as catalysts.
Figure 18: A novel family of helical chiral pyridine N-oxides OC-95 to OC-97.
Scheme 20: Desymmetrization of meso-epoxides catalyzed by OC-95 to OC-97.
Scheme 21: OC-98 catalyzed enantioselective desymmetrization of meso-epoxides by SiCl4.
Beilstein J. Org. Chem. 2013, 9, 1613–1619, doi:10.3762/bjoc.9.184
Graphical Abstract
Scheme 1: Strategies towards isothiocyanates.
Scheme 2: Flow approach towards isothiocyanates.
Beilstein J. Org. Chem. 2013, 9, 1487–1491, doi:10.3762/bjoc.9.169
Graphical Abstract
Figure 1: Structural formula of TEMPO (1), AZADO (2), TCNQF4 (3) and thiourea (4).
Scheme 1: Difference of the reaction products from TEMPO (1) and AZADO (2) with TCNQF4 (3).
Figure 2: Molecular structure of the adduct 5 obtained by X-ray analysis.
Scheme 2: A plausible mechanism of the reaction of AZADO (2) with TCNQF4 (3).
Figure 3: UV–vis spectra of 2 (red line), 3 (blue line) and 5 (green line).
Scheme 3: The reaction of 2 with 4 to form 6.
Figure 4: Crystal structure of the inclusion compound 6 obtained by X-ray analysis.
Beilstein J. Org. Chem. 2013, 9, 960–965, doi:10.3762/bjoc.9.110
Graphical Abstract
Figure 1: General approach for the use of dendritic catalysts in a dialysis bag.
Scheme 1: Synthesis of water-soluble iridium catalyst 3.
Scheme 2: Synthesis of the desymmetrized bipyridine 8.
Scheme 3: Attachment of the adapted ligand 8 to the dendrimers via a multi-isocyanate coupling, followed by i...
Scheme 4: Catalytic reductive amination of valine (18) via unfavorable equilibrium reactions in water.
Figure 2: Formation of 19 catalyzed by the three iridium catalysts.
Figure 3: Reaction setup to perform compartmentalized catalysis.
Figure 4: G3 catalyst 16 activity in dialysis device.
Figure 5: G4 catalyst 17 activity in subsequent runs.
Beilstein J. Org. Chem. 2013, 9, 628–632, doi:10.3762/bjoc.9.70
Graphical Abstract
Scheme 1: Carbolithiation of ureas 1.
Scheme 2: Diastereospecific carbolithiation of ureas 3.
Scheme 3: Diastereospecific carbolithiation of ureas 5.
Figure 1: X-ray crystal structure of urea 6c.
Scheme 4: Synthesis of N-alkenyl carbamates 9–11.
Figure 2: X-ray crystal structure of carbamate E-10.
Scheme 5: Umpolung carbolithiation of carbamates 9 and 10.
Beilstein J. Org. Chem. 2013, 9, 503–509, doi:10.3762/bjoc.9.54
Graphical Abstract
Figure 1: Biologically active 1,2,4-benzothiadiazine 1,1-dioxide derivatives.
Scheme 1: Retrosynthesis analysis of RSV inhibitors.
Scheme 2: Preparation of 3-ethoxy-1,2,4-benzothiadiazine 1,1-dioxide. Reagent and conditions: (i) (COCl)2, DM...
Scheme 3: Rationalization of the formation of compound 13.
Scheme 4: Preparation of benzothiadiazine-3-one 1,1-dioxide derivatives by acid-catalyzed hydrolysis; reagent...
Beilstein J. Org. Chem. 2012, 8, 1825–1830, doi:10.3762/bjoc.8.209
Graphical Abstract
Scheme 1: Ring-opening polymerization (ROP) of lactide with TBD or the acyclic guanidine 1 as catalysts [16,18].
Scheme 2: Illustration of a photoswitchable guanidine catalyst for the ROP of lactide and the corresponding t...
Scheme 3: Synthesis of guanidine 2E.
Figure 1: ORTEP image of the single-crystal X-ray structure of guanidine 2E, as well as a rotated close-up of...
Figure 2: UV–vis spectra of guanidine 2 in acetonitrile, c = 3.9·10−5 mol/L. (a) E→Z isomerization with irrad...
Scheme 4: Guanidine 11 as a catalyst in the ROP of rac-lactide (catalyst/initiator/monomer ratio = 10:1:100).
Figure 3: Supposed intermediates resulting from either a cyclohexane-substituted guanidine (a) [18] or an aromati...
Beilstein J. Org. Chem. 2012, 8, 1452–1457, doi:10.3762/bjoc.8.165
Graphical Abstract
Figure 1: The conjugated addition to unsaturated 1,4-diketone 1.
Figure 2: Organocatalysts screened.
Figure 3: Proposed transition state.
Figure 4: Calculated (red) and experimental (blue) IR (A) and VCD spectrum (B) of compound (R)-3a.
Beilstein J. Org. Chem. 2012, 8, 1443–1451, doi:10.3762/bjoc.8.164
Graphical Abstract
Figure 1: General structure of sulfoximines 1 and one of the enantiomers of S-methyl-S-phenylsulfoximine ((S)-...
Figure 2: Structures of chiral mono- and bifunctional (bis-)thioureas that have been used as organocatalysts.
Scheme 1: Synthesis of compound (S)-3.
Scheme 2: Organocatalytic desymmetrization of the cyclic anhydride 4 with (S)-3.
Scheme 3: Attempted synthesis of sulfonimidoyl-substituted thiourea (R)-9.
Scheme 4: Synthesis of the sulfonimidoyl-containing thioureas (S)-12 and (S)-13.
Scheme 5: Syntheses of ethylene-linked sulfonimidoyl-containing thioureas (SS,SC)-18 and (RS,SC)-19.
Beilstein J. Org. Chem. 2012, 8, 1406–1442, doi:10.3762/bjoc.8.163
Graphical Abstract
Scheme 1: Reactions for the methyl cation affinity (MCA) of a neutral Lewis base (1a), an anionic Lewis base ...
Figure 1: MCA values of monosubstituted amines of general formula Me2N(CH2)nH (n = 1–7, in kJ/mol).
Scheme 2: Systematic dependence of MCA.
Scheme 3: Trends in amine MCA values.
Figure 2: Eclipsing interactions in the best conformation of N+Me(iPr)3 (16Me) (left), and the corresponding ...
Scheme 4: General expression for the chain-length dependence of MCA values.
Figure 3: MCA values of monosubstituted phosphanes of general formula Me2P(CH2)nH (n = 1–8, in kJ/mol).
Figure 4: MCA values of monosubstituted phosphanes of general formula PMe2(CH(CH2)n+1) (n = 1–8, in kJ/mol).
Figure 5: The MCA values of n-butyldiphenylphosphane (102) and its (αα-/ββ-/γγ-) dimethylated analogues.
Figure 6: MCA values of phosphanes Me2P–NR2 with cyclic and acyclic amine substituents.
Figure 7: MCA values of phosphanes PMe2R connected to α,α- and β,β-position of nitrogen containing cyclic sub...
Scheme 5: Reactions for the benzhydryl cation affinity (BHCA) of a Lewis base (5a) and pyridine (5b).
Figure 8: Comparison of BHCA values (kJ/mol) and nucleophilicity parameters N for sterically unbiased pyridin...
Scheme 6: Reactions for the trityl cation affinity (THCA) of a Lewis base (6a) and pyridine (6b).
Figure 9: Comparison of MCA, BHCA, and TCA values of selected Lewis bases.
Scheme 7: Correlations of BHCA/TCA values with the respective MCA data for sterically unbiased systems (exclu...
Figure 10: Scheme for the angle d(RXRR) measurements.
Scheme 8: Reactions for the Mosher's cation affinity (MOSCA) of a Lewis base.
Scheme 9: Reactions for the acetyl cation affinity (ACA) of a Lewis base (9a) and pyridine (9b).
Figure 11: Structure of the acetylated pyridine 380 (380Ac).
Scheme 10: Reaction for the Michael-acceptor affinity (MAA) of a Lewis base.
Figure 12: Inverted reaction free energies for the addition of N- and P-based Lewis bases to three different M...
Figure 13: Correlation between MCA values and affinity values towards three different Michael acceptors.
Scheme 11: (a) General definition for a methyl cation transfer reaction between Lewis bases LB1 and LB2, and (...
Figure 14: The energetically best conformations of Pn-Bu3 (120_1, top) and (120_2, bottom).
Figure 15: Relative order of the conformations 120_1 to 120_7 depending on the level of theory.
Figure 16: The structure of the energetically best conformations of 120Me.
Beilstein J. Org. Chem. 2012, 8, 1318–1332, doi:10.3762/bjoc.8.151
Graphical Abstract
Figure 1: Formation of and coalescence of a polymer sample from its crystalline cyclodextrin inclusion comple...
Figure 2: Crystal structures and wide-angle X-ray diffractograms of neat (a) cage and (b) columnar IC γ-CD [20].
Figure 3: DSC cooling scans of as-received (upper) and coalesced N-6 (lower) [58].
Figure 4: DSC heating scans for asr-PVAc (upper) and c-PVAc coalesced from its γ-CD IC (lower) [72].
Figure 5: Melt-crystallization curves of as-received and coalesced PCL observed at 20, 10, 5, and 1 °C/min co...
Figure 6: X-ray diffraction patterns of as-synthesized PCL-b-PLLA films (a) and coalesced PCL-b-PLLA films (b...
Figure 7: Polarizing photomicrographs of (a) PLLA, (b) PCL, (c) solution-cast, and (d) coalesced PLLA/PCL ble...
Figure 8: X-ray diffractograms of (a) pure PCL and (b) PLLA and PCL/PLLA blends obtained by casting from diox...
Figure 9: MDSC scans of the (a) first and (b) second heating runs recorded for the PC/PMMA/PVAc-2 blend. The ...
Figure 10: Storage modulus, loss modulus, and apparent viscosity (G’, G’’, and n*, respectively) for asr- and ...
Figure 11:
Crystalline all trans (t) and γ-CD-included g±tg
conformations of PET [76].
Figure 12: DSC scans for p-PET [70].
Figure 13: DSC cooling scans from the melts of (I) asr-N-6, (II) nuc-N-6, and (III) asr/nuc N-6 film sandwich....
Figure 14: Mechanical properties of N-6 films [62].
Figure 15: Tensile testing of as-received/as-received and as-received/nucleated nylon-6 film sandwiches conduc...
Beilstein J. Org. Chem. 2012, 8, 514–521, doi:10.3762/bjoc.8.58
Graphical Abstract
Figure 1: Structure of trehalose (1), validoxylamine A (2), 1-thiatrehazolin (3), trehalostatin (4), casuarin...
Figure 2: Structure of nojirimycin-based (7, 8) and pyrrolidine-based (9) leads.
Figure 3: Structures of potential inhibitors 10–21.
Scheme 1: Synthesis of nojirimycin-based inhibitors 10,12 and 13. Reagents and conditions: (a) H2, Pd/C, NH4O...
Scheme 2: Synthesis of pyrrolidine derivatives 14, 16, 17 and 19. Reagents and conditions: (a) H2, Pd(OH)2/C,...
Scheme 3: Synthesis of pyrrolidines 20 and 21. Reagents and conditions: (a) H2, Pd/C, MeOH, HCl; (b) octanal,...
Figure 4: Histogram of the inhibitory activity of compounds 7–10, 12–14, 16 and 20. Derivatives 10, 14 and 16...